Chiba, Japan

Seikichi Kobaru


Average Co-Inventor Count = 3.6

ph-index = 2

Forward Citations = 12(Granted Patents)


Location History:

  • Chiba, JP (1993 - 1994)
  • Funabashi, JP (1996)

Company Filing History:


Years Active: 1993-1996

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Seikichi Kobaru: Innovator in Pharmaceutical Development

Introduction

Seikichi Kobaru is a notable inventor based in Chiba, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds with therapeutic potential. With a total of 3 patents to his name, Kobaru's work has garnered attention in the scientific community.

Latest Patents

Kobaru's latest patents include a compound produced by a strain of Micromonospora, specifically the novel compound BU-4664L and its derivatives. This compound is produced through the fermentation of Micromonospora sp. M990-6 and exhibits anti-inflammatory and/or anti-tumor cell activities. Additionally, he has developed a fermentation process for producing BMY-28960 and desxylosyl BMY-28960, along with a novel BMY-28960-producing organism belonging to the genus Actinomadura, designated as strain AB 1236 (ATCC 55208).

Career Highlights

Kobaru is currently associated with Bristol-Myers Squibb Company, where he continues to advance his research and development efforts. His work has been instrumental in the discovery of new therapeutic agents that hold promise for treating various medical conditions.

Collaborations

Throughout his career, Kobaru has collaborated with esteemed colleagues, including Tamotsu Furumai and Masami Hatori. These partnerships have facilitated the exchange of ideas and expertise, further enhancing the impact of his research.

Conclusion

Seikichi Kobaru's innovative contributions to pharmaceutical development highlight his role as a key inventor in the industry. His patents reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…